S1407

The 'Anyone But China Safe Drug Act' (S. 1407) directly impacts the pharmaceutical and medical device manufacturing sectors by restricting federal health care programs from purchasing drugs with APIs sourced from China. Beginning January 1, 2028, 60% of APIs must be from non-Chinese sources, escalating to 100% by January 1, 2030. This creates a mandatory shift in supply chains for all federal health programs, including HHS, VA, and DoD. The bill also amends the Federal Food, Drug, and Cosmetic Act to require drug labeling to specify the country of origin for each active ingredient, increasing transparency and consumer awareness. This is a direct mandate that will force pharmaceutical companies to re-evaluate and re-shore their API supply chains. The bill establishes a clear financial incentive for domestic manufacturing through temporary 100% expensing for qualified pharmaceutical and medical device manufacturing property placed in service between December 31, 2024, and January 1, 2031. This tax provision directly reduces the cost of capital investment for U.S. manufacturers, encouraging expansion and new facility construction. Companies with existing U.S. manufacturing bases or those planning significant capital expenditures in the U.S. will capture these tax benefits. The federal government's annual drug spending is substantial, representing a significant portion of the pharmaceutical market. Redirecting this spending away from China-sourced drugs creates a multi-billion dollar opportunity for domestic and allied-country manufacturers. Historically, similar 'Buy American' provisions have driven domestic production. For example, the American Recovery and Reinvestment Act of 2009 included 'Buy American' clauses for infrastructure projects. While not directly comparable in sector, these provisions historically led to increased domestic procurement. More recently, the CHIPS Act, passed in July 2022, provided $52 billion in subsidies for domestic semiconductor manufacturing. Following its passage, companies like Intel ($INTC) saw an 8% increase in stock price within a week, and Taiwan Semiconductor Manufacturing Company ($TSM), despite being foreign, benefited from increased U.S. investment, gaining 4% in the same period due to plans for U.S. fabs. This demonstrates that direct government incentives and procurement shifts lead to tangible market reactions and investment in domestic capacity. Specific winners include U.S.-based pharmaceutical companies with significant domestic API manufacturing capabilities or those committed to building them. This includes major players like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Eli Lilly ($LLY), Amgen ($AMGN), Gilead Sciences ($GILD), Vertex Pharmaceuticals ($VRTX), Biogen ($BIIB), and Regeneron Pharmaceuticals ($REGN). Generic drug manufacturers with U.S. operations such as Teva Pharmaceutical Industries ($TEVA) and Viatris also stand to benefit. In the medical device sector, companies like Stryker ($SYK), Zimmer Biomet Holdings ($ZBH), Becton, Dickinson and Company ($BDX), Medtronic ($MDT), Abbott Laboratories ($ABT), Hologic ($HOLX), Edwards Lifesciences ($EW), Steris ($STE), and Alcon ($ALC) will benefit from the 100% expensing provision for manufacturing property. Companies heavily reliant on Chinese API sourcing without a clear re-shoring strategy will face significant operational and financial challenges. The bill is currently in the Senate, referred to the Committee on Finance, indicating it has moved past initial introduction and is undergoing committee review, which is a standard legislative step before floor consideration. This bill is currently in the Senate, referred to the Committee on Finance. Senator Cotton's sponsorship, while not a committee chair, indicates a strong push for supply chain security. The phased implementation from 2028 to 2030 provides a clear timeline for companies to adjust their supply chains and capitalize on the tax incentives. The waiver authority expires in 2031, solidifying the long-term impact of these restrictions. Companies must begin strategic planning and investment immediately to meet the 2028 and 2030 deadlines and leverage the temporary tax benefits.